RADIOLOGY & IMAGING
Supporting radiologists to spot early signs of cancer, however large the workload Working symbiotically, human and machine are now detecting even the most difficult to spot signs of cancer – the signals that might otherwise have been overlooked, especially where radiologists are under increased time pressure. Importantly, the software has the potential to process heavy workloads at high speed too, allowing experienced radiologists to comfortably and reliably assess more cases per hour. It isn’t only in the reading of baseline studies and complex follow-up comparisons that AI-based technology is leaving its mark, and lightening workloads. The software automatically extracts lung nodules from medical images and provides comparable volumetric measurements that help to assess findings. It also makes short work of planning further patient treatment, by matching findings and established reporting guidelines including management recommendations. For hard-pressed health services, and at-risk populations, use of AI-based detection techniques in mass-scale lung cancer screening is a win-win. Thanks to our implementation of Veolity directly for large OEM healthcare equipment providers, and via strategic distribution partnerships including that with SynApps Solutions in the UK, MeVis Medical Solutions AG is recognised to be the world’s leading specialist in image-based lung cancer
screening solutions - with established deployments and continuously increasing enquiries worldwide. This illustrates the scale of the technology’s potential in making more of radiologists’ time, and improving outcomes for lung cancer patients.
As instances of cancer continue to rise, it is critical that medical professionals are able to draw on every tool available to them, to keep ahead of symptoms and apply early treatment.
According to a study of 4 million cancer patients reported in Lancet Oncology,2
the
UK had the lowest five-year survival rate for lung cancer (14.7% between 2010-2014) compared to other high-income nations, specifically Australia, Canada, Denmark, Ireland, New Zealand and Norway (Canada had the highest survival rate at 21.7%). It is these comparatively poor results that have prompted proactive new measures to improve diagnosis. Certainly, better patient outcomes and more effective use of healthcare budgets depend on the success of intensified screening initiatives, supported by smarter tools that enable radiologists to analyse and process their findings quickly, efficiently and reliably.
References
1 Cancer – key facts. World Health Organization, September 2018
2 The Lancet Oncology, Sept. 11, 2019:
https://www.thelancet.com/journals/lanonc/ article/PIIS1470-2045(19)30456-5/fulltext
About the author CSJ
Daniel Drieling is product manager at MeVis Medical Solutions. Headquartered in Bremen, Germany, the company develops and supplies intelligent software and services for image processing in medicine. MeVis contributes to the early detection and diagnostics of cancer, enabling early, tailor-made treatments of the disease. Internationally, MeVis Medical Solutions distributes its systems via a network of strategic systems integration partners such as SynApps Solutions in the UK.
Visit us at MEDICA 18TH -21ST November Hall 5/Stands E12 & E13
NOVEMBER 2019
WWW.CLINICALSERVICESJOURNAL.COM I
53
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104
